Pharming Group N.V annual gross profit
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V Gross Profit Growth & History (PHAR)
Pharming Group N.V's gross profit was $330.6M for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $330.6M | $68.8M | +26.29% |
| 2024 | 2024-12-31 | $261.8M | $41.7M | +18.94% |
| 2023 | 2023-12-31 | $220.1M | $32.0M | +17.04% |
| 2022 | 2022-12-31 | $188.1M | $10.3M | +5.81% |
| 2021 | 2021-12-31 | $177.7M | −$10.9M | −5.78% |
| 2020 | 2020-12-31 | $188.6M | $23.2M | +14.01% |
| 2019 | 2019-12-31 | $165.5M | — | — |
Pharming Group N.V gross profit trends
Over the last five fiscal years, Pharming Group N.V's gross profit increased from $188.6M to $330.6M, a change of $142.0M.
About the metric
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
Calculation and source
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...